Targeting tumor necrosis factor-α as a potential therapy in inflammatory skin diseases

Current Opinion in Investigational Drugs

Volumn 3, Issue 11, 2002, Pages 1590-1595

  Girolomoni, Giampiero ^a   Pastore, Saveria ^a   Albanesi, Cristina ^a   Cavani, Andrea ^a  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

Author keywords

Etanercept; Inflammation; Infliximab; Psoriasis; TNF

Indexed keywords

ADALIMUMAB; AFELIMOMAB; ANTIINFLAMMATORY AGENT; ANTIPSORIASIS AGENT; ANTIRHEUMATIC AGENT; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; ETRETIN; FUMARIC ACID DIMETHYL ESTER; INFLIXIMAB; LENERCEPT; METHOTREXATE; ONERCEPT; PEGSUNERCEPT; PIMECROLIMUS; PLACEBO; TACROLIMUS; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANTIINFLAMMATORY ACTIVITY; BEHCET DISEASE; CANCER; CANCER RISK; CLINICAL TRIAL; DISCOID LUPUS ERYTHEMATOSUS; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; ERYTHEMA; GASTROINTESTINAL INFECTION; GRAFT VERSUS HOST REACTION; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INJECTION PAIN; INJECTION SITE; MULTICENTER STUDY; NAUSEA; NECROTIZING ARTERITIS; NONHUMAN; PATHOGENESIS; PRURITUS; PSORIASIS; PYODERMA GANGRENOSUM; REVIEW; RHEUMATOID ARTHRITIS; RHINITIS; SIGNAL TRANSDUCTION; SKIN CARCINOMA; SKIN EDEMA; SKIN INFLAMMATION; SKIN MANIFESTATION; SQUAMOUS CELL CARCINOMA; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DERMATITIS; DRUG DELIVERY SYSTEMS; HUMANS; INFLAMMATION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036881426     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Locksley RM, Killeen N, Lenardo MJ: The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell (2001) 104:487-501. A systematic and comprehensive review discussing the multiple biological role of TNF/TNF-R superfamilies.
2. Chen G, Goeddel DV: TNF-R1 signalling: A beautiful pathway. Science (2002) 296:1634-1635.
3. Baud V, Karin M: Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol (2001) 11:372-377.
4. MacEwan DJ: TNF receptor subtype signalling: Differences and cellular consequences. Cell Signal (2002) 14:477-492.
5. Pasparakis M, Courtois G, Hafner M, Schmidt-Supprian M, Nenci A, Toksoy A, Krampert M, Goebeler M, Gillitzer R, Israel A, Krieg T et al: TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2. Nature (2002) 417:861-866. An outstanding paper showing that mice with epidermis-specific deletion IKK2 develop a severe inflammatory skin disease, which is caused by TNFα soon after birth. This study demonstrates the master regulatory role played by TNF-R1 and keratinocytes in the initiation of skin inflammation.
6. Cumberbatch M, Dearman RJ, Griffiths CE, Kimber I: Langerhans cell migration. Clin Exp Dermatol (2000) 25:413-418.
7. Sebastiani S, Albanesi C, De Pità O, Puddu P, Cavani A, Girolomoni G: The role of chemokines in allergic contact dermatitis. Arch Dermatol Res (2002) 293:552-559.
8. Albanesi C, Cavani A, Girolomoni G: IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-I expression and chemokine production in human keratinocytes: Synergistic of antagonist effects with IFN-γ and TNF-α. J Immunol (1999) 162:494-502.
9. Traidl C, Sebatiani S, Albanesi C, Merk HF, Puddu P, Girolomoni G, Cavani A: Disparate cytotoxic activity of nickel-specific CD8+ and CD4+ T cell subsets against keratinocytes. J Immunol (2000) 165:3058-3064.
10. Qin JZ, Bacon P, Chaturvedi V, Nickoloff BJ: Role of NF-κB activity in apoptotic response of keratinocytes mediated by interferon-γ tumor necrosis factor-α, and tumor necrosis factor-related apoptosis-inducing ligand. J Invest Dermatol (2001) 117:898-907.
11. Mori R, Kondo T, Ohshima T, Ishida Y, Mukaida N: Accelerated wound healing in tumor necrosis factor receptor p55-deficient mice with reduced leukocyte infiltration. FASEB J (2002) 16:963-974.
12. Krueger JG: The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol (2002) 46:1-23. This is a comprehensive review summarizing current understanding of the pathogenesis of psoriasis and discussing the targets for novel biological therapeutic agents.
13. Asadullah K, Volk H-D, Sterry W: Novel immunotherapies for psoriasis. Trends Immunol (2002) 23:47-53. This is a comprehensive review summarizing current understanding of the pathogenesis of psoriasis and discussing the targets for novel biological therapeutic agents.
14. Giustizieri ML, Mascia F, Frezzolini A, De Pità O, Chinni ML, Giannetti A, Girolomoni G, Pastore S: Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T cell-derived cytokines. J Allergy Clin Immunol (2001) 107:871-877.
15. Albanesi C, Scarponi C, Sebatiani S, Cavani A, Federici M, Sozzani S, Girolomoni G: A cytokine-to-chemokine axis between T lymphocytes and keratinocytes can favor Th1 cell accumulation in chronic inflammatory skin diseases. J Leukocyte Biol (2001) 70:617-623.
16. Reich K, Mossner R, Konig IR, Westphal G, Ziegler A, Neumann C: Promoter polymorphisms of the genes encoding tumor necrosis factor-α and interleukin-1β are associated with different subtypes of psoriasis characterized by early and late disease onset. J Invest Dermatol (2002) 118:155-163
17. Craven NM, Jackson CW, Kirby B, Perrey C, Pravica V, Hutchinson IV, Griffiths CE: Cytokine gene polymorphisms in psoriasis. Br J Dermatol (2001) 144:849-853.
18. Corsini E, Terzoli A, Bruccoleri A, Marinovich M, Galli CL: Induction of tumor necrosis factor-α in vivo by a skin irritant, tributyltin, through activation of transcription factors: Its pharmacological modulation by anti-inflammatory drugs. J Invest Dermatol (1997) 108:892-896.
19. Kondo S, Sauder DN: Tumor necrosis factor (TNF) receptor type 1 (p55) is a main mediator for TNF-α-induced skin inflammation. Eur J Immunol (1997) 27:1713-1718.
20. Wang B, Feliciani C, Free I, Cai Q, Sauder DN: Insights into molecular mechanisms of contact hypersensitivity gained from gene knockout studies. J Leukocyte Biol (2001) 70:185-191.
21. Feliciani C, Toto P, Amerio P, Pour SM, Coscione G, Shivji G, Wang B, Sauder DN: In vitro and in vivo expression of interleukin-1α and tumor necrosis factor-α mRNA in pemphigus vulgaris: Interleukin-1α and tumor necrosis factor-α are involved in acantholysis. J Invest Dermatol (2000) 114:71-77.
22. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G: Thalidomide exerts its inhibitory action on tumor necrosis factor α by enhancing mRNA degradation. J Exp Med (1993) 177:1675-1680.
23. Nghiem P, Pearson G, Langley RG: Tacrolimus and pimecrolimus: From clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol (2002) 46:228-241.
24. Loewe R, Holnthoner W, Groger M, Pillinger M, Gruber F, Mechtcheriakova D, Hofer E, Wolff K, Wolff K, Petzelbauer P: Dimethylfumarate inhibits TNF-induced nuclear entry of NF-κB/p65 in human endothelial cells. J Immunol (2002) 168:4781-4787.
25. Feldmann M: Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol (2002) 2:364-371. A reappraisal on recent developments in the use of anti-TNF α therapy in rheumatoid arthritis.
26. Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, Wagner C: Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther (2002) 301:418-426. Infiximab and etanercept show distinct TNFα binding characteristics.
27. Gorman JD, Sack KE, Davis JC Jr: Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α. N Engl J Med (2002) 346:1349-1356.
28. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ: Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial. Lancet (2000) 356:385-390. A double-blind, placebo-controlled study demonstrating the efficacy and safety of etanercept in the treatment of psoriatic arthritis and psoriasis.
29. Mease PJ: Tumor necrosis factor (TNF) in psoriatic arthritis: Pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis (2002) 61:298-304.
30. Wollina U, Konrad H: Treatment of recalcitrant psoriatic arthritis with anti-tumor necrosis factor-α antibody. J Eur Acad Dermatol Venereol (2002) 16:127-129.
31. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P: Maintenance infliximab for Chrohn's disease: The ACCENT I randomised trial. Lancet (2002) 359:1541-1549.
32. Iyer S, Yamauchi P, Lowe NJ: Etanercept for severe psoriasis and psoriatic arthritis: Observations on combination therapy. Br J Dermatol (2002) 146:118-121.
33. Oh CJ, Das KM, Gottlieb AB: Treatment with anti-tumor necrosis factor α (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol (2000) 42:829-830.
34. Kirby B, Marsland AM, Carmichael AJ, Griffiths CE: Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate. Clin Exp Dermatol (2001) 26:27-29.
35. Ogilvie AL, Antoni C, Dechant C, Manger B, Kalden JR, Schuler G, Luftl M: Treatment of psoriatic arthritis with antitumour necrosis factor-α antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol (2001) 144:587-589.
36. O'Quinn RP, Miller JL: The effectiveness of tumor necrosis factor α antibody (infliximab) in treating recalcitrant psoriasis: A report of 2 cases. Arch Dermatol (2002) 138:644-648.
37. Schopf RE, Aust H, Knop J: Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor α, infliximab. J Am Acad Dermatol (2002) 46:886-891.
38. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB: Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomised trial. Lancet (2001) 357:1842-1847. A double-blind, placebo-controlled study demonstrating the efficacy and safety of infliximab in the treatment of plaque-type psoriasis.
39. Robertson LP, Hickling P: Treatment of recalcitrant orogenital ulceration of Behcet's syndrome with infliximab. Rheumatology (2001): 40:473-474.
40. Goossens PH, Verburg RJ, Breedveld FC: Remission of Behcet's syndrome with tumor necrosis factor α blocking therapy. Ann Rheum Dis (2001) 60:637.
41. Voigtlander C, Luftl M, Schuler G, Hertl M: Infliximab (anti-tumor necrosis factor α antibody): A novel, highly effective treatment of recalcitrant subcorneal pustular dermatosis (Sneddon-Wilkinson disease). Arch Dermatol (2001) 137:1571-1574.
42. Tan MH, Gordon M, Lebwohl O, George J, Lebwohl MG: Improvement of pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor α monoclonal antibody. Arch Dermatol (2001) 137:930-933.
43. Batres LA, Mamula P, Baldassano RN: Resolution of severe peristomal pyoderma gangrenosum with infliximab in a child with Crohn disease. J Pediatr Gastroenterol Nutr (2002) 34:558-560.
44. Limova M, Bolce R: Management of pyoderma gangrenosum with infliximab (Remicade). Ann Dermatol Venereol (2002) 129:1S580-1S581.
45. Mahadevan U, Sandborn WJ: Infliximab for the treatment of orofacial Crohn's disease. Inflamm Bowel Dis (2001) 7:38-42.
46. Bens G, Laharie D, Beylot-Barry M, Vergier B, Noblesse I, Amouretti M: Bipolar pyostomatitis vegetans treated with infliximab. Ann Dermatol Venereol (2002) 129:1S569.
47. Sullivan T, Kirsner R, Welsh E, Kerdel F, Burdick A: Infliximab for the treatment of hidradenitis suppurativa. Ann Dermatol Venereol (2002) 129:1S705.
48. Kobbe G, Schneider P, Rohr U, Fenk R, Neumann F, Aivado M, Dietze L, Kronenwett R, Hunerliturkoglu A, Haas R: Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse anti-TNFα antibody. Bone Marrow Transplant (2001) 28:47-49.
49. Day R: Adverse reactions to TNF-α inhibitors in rheumatoid arthritis. Lancet (2002) 359:540-541. An informative mini-review discussing adverse reactions to infliximab and etanercept.
50. Zeltser R, Valle L, Tanck C, Holyst MM, Ritchlin C, Gaspari AA: Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: A recombinant tumor necrosis factor α receptor: Fc fusion protein. Arch Dermatol (2001) 137:893-899.
51. Brion PH, Mittal-Henkle A, Kalunian KC: Autoimmune skin rashes associated with etanercept for rheumatoid arthritis. Ann Intern Med (1999) 131:634.
52. Galaria NA, Werth VP, Schumacher HR: Leukocytoclastic vasculitis due to etanercept. J Rheumatol (2000) 27:2041-2044.
53. Misery L, Perrot JL, Gentil-Perret A, Pallot-Prades B, Cambazard F, Alexandre C: Dermatological complications of etanercept therapy for rheumatoid arthritis. Br J Dermatol (2002) 146:334-335.
54. Smith KJ, Skelton HG: Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor α receptor IgG1-Fc fusion complex therapy. J Am Acad Dermatol (2001) 45:953-956.
55. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM: Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med (2001) 345:1098-1104.